1196 related articles for article (PubMed ID: 31722094)
1. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
2. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization.
Wu YW; Lee DY; Lu YL; Delila L; Nebie O; Barro L; Changou CA; Lu LS; Goubran H; Burnouf T
Platelets; 2023 Dec; 34(1):2237134. PubMed ID: 37580876
[TBL] [Abstract][Full Text] [Related]
3. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
4. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X
Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131
[TBL] [Abstract][Full Text] [Related]
5. Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer.
Jusu SM; Obayemi JD; Salifu AA; Nwazojie CC; Uzonwanne V; Odusanya OS; Soboyejo WO
Sci Rep; 2020 Aug; 10(1):14188. PubMed ID: 32843673
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
7. Amplification of anticancer efficacy by co-delivery of doxorubicin and lonidamine with extracellular vesicles.
Li H; Xu W; Li F; Zeng R; Zhang X; Wang X; Zhao S; Weng J; Li Z; Sun L
Drug Deliv; 2022 Dec; 29(1):192-202. PubMed ID: 34984953
[TBL] [Abstract][Full Text] [Related]
8. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-Loaded Folate-Coated pH-Sensitive Liposomes Enhance Cellular Uptake and Antitumor Activity.
Monteiro LOF; Fernandes RS; Castro L; Reis D; Cassali GD; Evangelista F; Loures C; Sabino AP; Cardoso V; Oliveira MC; Branco de Barros A; Leite EA
Mol Pharm; 2019 Aug; 16(8):3477-3488. PubMed ID: 31257891
[TBL] [Abstract][Full Text] [Related]
10. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations.
Kim MS; Haney MJ; Zhao Y; Yuan D; Deygen I; Klyachko NL; Kabanov AV; Batrakova EV
Nanomedicine; 2018 Jan; 14(1):195-204. PubMed ID: 28982587
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
12. Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors.
Ye J; Liu Y; Xia X; Meng L; Dong W; Wang R; Fu Z; Liu H; Han R
Oncol Rep; 2016 Jul; 36(1):399-409. PubMed ID: 27175803
[TBL] [Abstract][Full Text] [Related]
13. EGFR Targeted Paclitaxel and Piperine Co-loaded Liposomes for the Treatment of Triple Negative Breast Cancer.
Burande AS; Viswanadh MK; Jha A; Mehata AK; Shaik A; Agrawal N; Poddar S; Mahto SK; Muthu MS
AAPS PharmSciTech; 2020 May; 21(5):151. PubMed ID: 32440910
[TBL] [Abstract][Full Text] [Related]
14. Extracellular vesicles: Natural liver-accumulating drug delivery vehicles for the treatment of liver diseases.
Zhang G; Huang X; Xiu H; Sun Y; Chen J; Cheng G; Song Z; Peng Y; Shen Y; Wang J; Cai Z
J Extracell Vesicles; 2020 Dec; 10(2):e12030. PubMed ID: 33335695
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models.
Patel N; Kommineni N; Surapaneni SK; Kalvala A; Yaun X; Gebeyehu A; Arthur P; Duke LC; York SB; Bagde A; Meckes DG; Singh M
Int J Pharm; 2021 Sep; 607():120943. PubMed ID: 34324983
[TBL] [Abstract][Full Text] [Related]
16. Targeting claudin-4 enhances chemosensitivity in breast cancer.
Luo Y; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Goto K; Nishiguchi Y; Mori T; Kawahara I; Kondoh M; Kuniyasu H
Cancer Sci; 2020 May; 111(5):1840-1850. PubMed ID: 32086991
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.
Lv S; Tang Z; Li M; Lin J; Song W; Liu H; Huang Y; Zhang Y; Chen X
Biomaterials; 2014 Jul; 35(23):6118-29. PubMed ID: 24794923
[TBL] [Abstract][Full Text] [Related]
18. Active cargo loading into extracellular vesicles: Highlights the heterogeneous encapsulation behaviour.
Chen C; Sun M; Wang J; Su L; Lin J; Yan X
J Extracell Vesicles; 2021 Nov; 10(13):e12163. PubMed ID: 34719860
[TBL] [Abstract][Full Text] [Related]
19. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells.
Kim MS; Haney MJ; Zhao Y; Mahajan V; Deygen I; Klyachko NL; Inskoe E; Piroyan A; Sokolsky M; Okolie O; Hingtgen SD; Kabanov AV; Batrakova EV
Nanomedicine; 2016 Apr; 12(3):655-664. PubMed ID: 26586551
[TBL] [Abstract][Full Text] [Related]
20. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
